Covered recipient · General Payments record
DAVID A EICHENBAUM
Allopathic & Osteopathic Physicians Ophthalmology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$328,544.90
325 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $166,634.83 | 33 |
| Consulting Fee | $110,166.25 | 43 |
| Travel and Lodging | $29,699.26 | 86 |
| Food and Beverage | $9,789.56 | 159 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,400.00 | 2 |
| Current or prospective ownership or investment interest | $3,855.00 | 1 |
| Honoraria | $1,000.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $107,425.25 | 66 |
| Allergan Inc. | $74,235.67 | 84 |
| Genentech USA, Inc. | $68,616.63 | 67 |
| Dutch Ophthalmic, USA | $21,332.14 | 19 |
| Genentech, Inc. | $16,400.78 | 24 |
| Regeneron Healthcare Solutions, Inc. | $6,812.65 | 14 |
| F. Hoffmann-La Roche AG | $6,645.83 | 4 |
| ThromboGenics, Inc. | $5,295.55 | 5 |
| Bausch & Lomb, a division of Bausch Health US, LLC | $4,912.28 | 9 |
| EyePoint Pharmaceuticals US, Inc. | $4,625.18 | 6 |
| US Retina LLC | $3,855.00 | 1 |
| Alimera Sciences, Inc. | $3,794.99 | 8 |
| Celgene Corporation | $2,790.00 | 4 |
| NotalVision | $1,321.08 | 2 |
| Ocular Therapeutix, Inc. | $156.90 | 8 |
| Ivantis, Inc | $116.62 | 1 |
| Spark Therapeutics, Inc. | $102.56 | 1 |
| Carl Zeiss Meditec, Inc. | $69.76 | 1 |
| Regeneron Pharmaceuticals, Inc. | $36.03 | 1 |
Page 4 of 7; records 151–200 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID A EICHENBAUM
NPI 1144251356 · CMS profile ID 279088
Allopathic & Osteopathic Physicians / Ophthalmology
ST PETERSBURG, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 7; records 151–200 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1144251356?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID A EICHENBAUM, NPI 1144251356, CMS profile ID 279088. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144251356?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). DAVID A EICHENBAUM, NPI 1144251356, CMS profile ID 279088. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144251356?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- DAVID A EICHENBAUM, NPI 1144251356, CMS profile ID 279088, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 7; records 151–200 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144251356?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
325 matching records · $328,544.90 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 325.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bausch & Lomb, a division of Bausch Health US, LLC | $1,500.00 | 07/23/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684408151 | CMS |
| Genentech USA, Inc. | $83.03 | 07/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681126777 | CMS |
| Genentech USA, Inc. | $1,327.18 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681355131 | CMS |
| Genentech USA, Inc. | $20.00 | 07/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681361275 | CMS |
| Genentech USA, Inc. | $147.92 | 07/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681368275 | CMS |
| Genentech USA, Inc. | $135.84 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681381851 | CMS |
| Genentech USA, Inc. | $337.82 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681391911 | CMS |
| Genentech USA, Inc. | $6,200.00 | 07/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 857128225 | CMS |
| ThromboGenics, Inc. | $22.02 | 07/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637737027 | CMS |
| Novartis Pharmaceuticals Corporation | $155.80 | 07/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658902013 | CMS |
| Novartis Pharmaceuticals Corporation | $197.13 | 07/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658902017 | CMS |
| Novartis Pharmaceuticals Corporation | $12,275.00 | 07/13/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658902021 | CMS |
| Novartis Pharmaceuticals Corporation | $125.24 | 07/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658902023 | CMS |
| Novartis Pharmaceuticals Corporation | $36.00 | 07/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658902027 | CMS |
| Novartis Pharmaceuticals Corporation | $25.72 | 07/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658902032 | CMS |
| Novartis Pharmaceuticals Corporation | $244.00 | 07/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797731 | CMS |
| Genentech, Inc. | $19.87 | 07/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681179033 | CMS |
| Genentech USA, Inc. | $44.65 | 06/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681290129 | CMS |
| Allergan Inc. | $5,000.00 | 06/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289947 | CMS |
| Allergan Inc. | $122.00 | 06/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289953 | CMS |
| Allergan Inc. | $114.30 | 06/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289957 | CMS |
| Allergan Inc. | $12.18 | 06/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289961 | CMS |
| Allergan Inc. | $132.22 | 06/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289965 | CMS |
| Allergan Inc. | $689.51 | 06/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289969 | CMS |
| Allergan Inc. | $5.00 | 06/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289972 | CMS |
| Allergan Inc. | $213.57 | 06/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289977 | CMS |
| Allergan Inc. | $140.30 | 06/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289979 | CMS |
| Novartis Pharmaceuticals Corporation | $2,563.00 | 06/26/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797713 | CMS |
| Novartis Pharmaceuticals Corporation | $2,563.00 | 06/25/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797707 | CMS |
| ThromboGenics, Inc. | $12.61 | 06/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637737025 | CMS |
| Genentech, Inc. | $387.50 | 06/13/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 708851255 | CMS |
| Novartis Pharmaceuticals Corporation | $319.55 | 06/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797735 | CMS |
| Novartis Pharmaceuticals Corporation | $570.80 | 06/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797741 | CMS |
| Novartis Pharmaceuticals Corporation | $8,200.00 | 06/13/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797745 | CMS |
| Novartis Pharmaceuticals Corporation | $112.26 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797751 | CMS |
| Novartis Pharmaceuticals Corporation | $24.07 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797757 | CMS |
| Novartis Pharmaceuticals Corporation | $256.60 | 06/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797763 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,020.00 | 06/13/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373497 | CMS |
| Genentech, Inc. | $1,550.00 | 06/12/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681174645 | CMS |
| Novartis Pharmaceuticals Corporation | $608.81 | 06/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797665 | CMS |
| Novartis Pharmaceuticals Corporation | $6,150.00 | 06/12/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797671 | CMS |
| Novartis Pharmaceuticals Corporation | $113.40 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797677 | CMS |
| Novartis Pharmaceuticals Corporation | $289.60 | 06/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658797685 | CMS |
| Allergan Inc. | $273.00 | 06/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289901 | CMS |
| Allergan Inc. | $119.12 | 06/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289907 | CMS |
| Allergan Inc. | $24.36 | 06/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289911 | CMS |
| Allergan Inc. | $182.05 | 06/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289915 | CMS |
| Allergan Inc. | $156.16 | 06/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289919 | CMS |
| Allergan Inc. | $4.00 | 06/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289923 | CMS |
| Allergan Inc. | $5,000.00 | 06/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670289927 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $4,485.88 | 4 |
| PY2025 | Principal investigator | $10,627,254.21 | 800 |
| PY2024 | Recipient | $8,932.27 | 4 |
| PY2024 | Principal investigator | $6,627,967.87 | 343 |
| PY2023 | Recipient | $1,925.65 | 3 |
| PY2023 | Principal investigator | $3,430,849.09 | 192 |
| PY2022 | Principal investigator | $3,798,346.45 | 192 |
| PY2021 | Recipient | $12,906.03 | 5 |
| PY2021 | Principal investigator | $3,082,081.64 | 207 |
| PY2020 | Recipient | $12,431.94 | 6 |
| PY2020 | Principal investigator | $3,643,159.02 | 144 |
| PY2019 | Recipient | $4,281.10 | 1 |
| PY2019 | Principal investigator | $1,501,447.49 | 88 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
804 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $4,796.00 | 12/30/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600451 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,543.00 | 12/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1175392016 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,430.77 | 12/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236304 |
| Principal investigator 1 | Genentech, Inc. | $4,155.00 | 12/26/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600456 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,517.80 | 12/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236297 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $88,096.50 | 12/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236301 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,953.25 | 12/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184280166 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,198.48 | 12/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184280168 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,198.48 | 12/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184280170 |
| Principal investigator 1 | Genentech, Inc. | $140.00 | 12/19/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600419 |
| Principal investigator 1 | Genentech, Inc. | $454.00 | 12/19/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600424 |
| Principal investigator 1 | Genentech, Inc. | $347.20 | 12/19/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600430 |
| Principal investigator 1 | Genentech, Inc. | $576.80 | 12/19/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600434 |
| Principal investigator 1 | Genentech, Inc. | $252.00 | 12/19/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600438 |
| Principal investigator 1 | Genentech, Inc. | $434.00 | 12/19/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600443 |
| Principal investigator 1 | Genentech, Inc. | $9,428.00 | 12/19/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600447 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,272.72 | 12/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184278216 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,089.93 | 12/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184278218 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,842.63 | 12/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184278220 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $33,044.70 | 12/19/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226100339 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,290.35 | 12/19/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226100346 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,904.95 | 12/19/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Fl | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107520 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,014.95 | 12/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236294 |
| Principal investigator 1 | Genentech, Inc. | $4,302.00 | 12/16/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646720 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,259.00 | 12/15/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175392049 |
| Principal investigator 1 | Genentech, Inc. | $3,472.00 | 12/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211637199 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,663.00 | 12/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175391904 |
| Principal investigator 1 | Genentech, Inc. | $4,051.00 | 12/11/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646657 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,919.90 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236285 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.36 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $264.60 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $222.86 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269925 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $487.29 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269929 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $572.88 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269933 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269935 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $609.84 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269937 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269939 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $185.69 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269941 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $115.88 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269943 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $249.48 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269945 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $482.84 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269947 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $92.40 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269949 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $71.31 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269951 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269953 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $105.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269957 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269959 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.14 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269961 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.91 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269965 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $226.90 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269967 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269969 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269971 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $516.82 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269973 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269975 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $93.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $646.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269979 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269981 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.14 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269983 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269985 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $516.82 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269987 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $93.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269989 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $264.60 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269991 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $105.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269993 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269995 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.97 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269997 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.36 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184269999 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270001 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $516.82 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270003 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270005 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $646.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270007 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270009 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $226.90 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270011 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.97 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270013 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.91 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270015 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.38 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270017 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $264.60 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270019 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270021 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270023 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270025 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $93.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270027 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $105.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270029 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270031 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.14 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270033 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $646.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270035 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $151.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270037 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270039 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270041 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $226.90 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270043 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.97 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270045 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.91 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270047 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.36 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270049 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $264.60 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $226.90 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270053 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $244.20 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270055 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $71.31 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270057 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270059 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $76.56 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270061 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $93.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270063 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $516.82 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270065 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270067 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.14 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270069 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $105.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $646.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270075 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270077 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $105.00 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270079 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.97 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270081 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.91 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270083 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.36 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270085 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $264.60 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270087 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270089 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270091 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270093 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $93.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270095 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $516.82 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270097 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270099 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.14 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270101 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $297.13 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270103 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $646.80 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270105 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270107 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $226.90 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270109 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.97 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270111 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.91 | 12/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184270113 |
| Principal investigator 1 | Genentech, Inc. | $171,725.00 | 12/08/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646715 |
| Principal investigator 1 | Genentech, Inc. | $1,828.00 | 12/05/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646652 |
| Principal investigator 1 | Genentech, Inc. | $13,358.00 | 12/04/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600426 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,054,794.52 | 12/04/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA | A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1190301991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634437 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 12/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FLORIDA | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211637204 |
| Principal investigator 1 | Genentech, Inc. | $2,660.00 | 12/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FLORIDA | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211637208 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 12/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FLORIDA | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211637212 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 12/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FLORIDA | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211637216 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,110.00 | 12/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236267 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $87,183.60 | 12/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236272 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $28,193.40 | 12/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236278 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $755.54 | 12/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236282 |
| Principal investigator 1 | Genentech, Inc. | $134.97 | 11/26/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600382 |
| Principal investigator 1 | Janssen Research & Development, LLC | $888.00 | 11/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1175391899 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,770.49 | 11/21/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236251 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,014.95 | 11/21/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236255 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $18,385.20 | 11/21/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236259 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $35,819.00 | 11/21/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236263 |
| Principal investigator 1 | Genentech, Inc. | $2,048.00 | 11/20/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600399 |
| Principal investigator 1 | Genentech, Inc. | $1,067.13 | 11/20/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600411 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,014.95 | 11/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236246 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,272.72 | 11/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184262157 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,098.12 | 11/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184262159 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,089.93 | 11/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184262161 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,953.25 | 11/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184262163 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,198.48 | 11/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184262165 |
| Principal investigator 1 | Roche TCRC, Inc. | $8,455.00 | 11/17/2025 | Non-covered Recipient Entity Pautler,Cohen,Findlay and Eichenbaum MD's | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211637230 |
| Principal investigator 1 | Genentech, Inc. | $904.40 | 11/14/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600360 |
| Principal investigator 1 | Genentech, Inc. | $11,415.00 | 11/14/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600365 |
| Principal investigator 1 | Genentech, Inc. | $3,805.00 | 11/14/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600369 |
| Principal investigator 1 | Genentech, Inc. | $848.28 | 11/14/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600373 |
| Principal investigator 1 | Genentech, Inc. | $6,660.00 | 11/14/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600377 |
| Principal investigator 1 | Genentech, Inc. | $434.00 | 11/14/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600385 |
| Principal investigator 1 | Genentech, Inc. | $4,155.00 | 11/14/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600394 |
| Principal investigator 1 | Genentech, Inc. | $358.83 | 11/14/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600404 |
| Principal investigator 1 | Genentech, Inc. | $454.00 | 11/14/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600415 |
| Principal investigator 1 | Genentech, Inc. | $405.65 | 11/14/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646702 |
| Principal investigator 1 | Genentech, Inc. | $6,365.00 | 11/14/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646742 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,623.00 | 11/14/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226100397 |
| Principal investigator 1 | Genentech, Inc. | $4,131.36 | 11/12/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646710 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,183.90 | 11/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236240 |
| Principal investigator 1 | Genentech, Inc. | $4,818.00 | 11/06/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600390 |
| Principal investigator 1 | ABBVIE INC. | $15,844.40 | 11/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY EICHENBAUM WHITE AND CRANE MDS PA | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202520051 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,105.00 | 11/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1175391994 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,436.50 | 11/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184257019 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,480.10 | 11/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184257021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634435 |
| Principal investigator 1 | Genentech, Inc. | $4,155.00 | 10/29/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600354 |
| Principal investigator 1 | Genentech, Inc. | $126.00 | 10/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211637195 |
| Principal investigator 1 | Genentech, Inc. | $2,689.00 | 10/29/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646707 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $135,418.70 | 10/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236224 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $60,367.50 | 10/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236227 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $64,069.20 | 10/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236232 |
| Principal investigator 1 | ABBVIE INC. | $80.76 | 10/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY EICHENBAUM WHITE AND CRANE MDS PA | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202518857 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,534.00 | 10/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1175392031 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,650.93 | 10/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221813720 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,505.53 | 10/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221813726 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,241.13 | 10/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221813734 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,706.93 | 10/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221813742 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,962.53 | 10/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221813751 |
| Principal investigator 1 | Genentech, Inc. | $5,425.00 | 10/24/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600356 |
| Principal investigator 1 | Genentech, Inc. | $12,936.00 | 10/17/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646643 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,098.12 | 10/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184251295 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,700.00 | 10/17/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226100451 |
| Principal investigator 1 | Genentech, Inc. | $6,267.00 | 10/16/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600349 |
| Principal investigator 1 | Genentech, Inc. | $4,375.00 | 10/16/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646639 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,220.95 | 10/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236219 |
| Principal investigator 1 | Genentech, Inc. | $4,790.00 | 10/09/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600343 |
| Principal investigator 1 | Genentech, Inc. | $6,098.00 | 10/09/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646647 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $200.00 | 10/09/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA (SAINT PETERSBURG) | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250238349 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,248.15 | 10/08/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236215 |
| Principal investigator 1 | Genentech, Inc. | $10,431.35 | 10/07/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646697 |
| Principal investigator 1 | Genentech, Inc. | $9,618.00 | 10/06/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646630 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634433 |
| Principal investigator 1 | Genentech, Inc. | $6,267.00 | 10/01/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600346 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,543.00 | 09/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175392043 |
| Principal investigator 1 | Genentech, Inc. | $31,873.00 | 09/26/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646634 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,836.80 | 09/26/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236211 |
| Principal investigator 1 | Genentech, Inc. | $1,385.00 | 09/24/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600315 |
| Principal investigator 1 | Genentech, Inc. | $11,629.00 | 09/24/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600331 |
| Principal investigator 1 | Genentech, Inc. | $5,312.00 | 09/24/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646736 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,220.00 | 09/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236206 |
| Recipient | F. Hoffmann-La Roche AG | $1,188.14 | 09/19/2025 | Covered Recipient Physician | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211535292 |
| Principal investigator 1 | Janssen Research & Development, LLC | $690.00 | 09/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391958 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,272.82 | 09/15/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221810640 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,318.00 | 09/15/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221810646 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,524.75 | 09/15/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221810653 |
| Principal investigator 1 | Genentech, Inc. | $4,066.00 | 09/11/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600335 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,089.93 | 09/11/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184236003 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,953.25 | 09/11/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184236005 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,272.72 | 09/11/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184236007 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,121.80 | 09/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236189 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,424.80 | 09/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236192 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,837.60 | 09/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236197 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,548.00 | 09/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236201 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $226.95 | 09/08/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410418 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $880.00 | 09/08/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410606 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $124.62 | 09/08/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410678 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 09/08/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410848 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $124.62 | 09/08/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410880 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,227.30 | 09/08/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410932 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $226.95 | 09/08/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411150 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $124.62 | 09/08/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411170 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $25,489.80 | 09/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236184 |
| Principal investigator 1 | Genentech, Inc. | $3,805.00 | 09/04/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600311 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 09/04/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600319 |
| Principal investigator 1 | Genentech, Inc. | $7,793.00 | 09/04/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600324 |
| Principal investigator 1 | Genentech, Inc. | $3,805.00 | 09/04/2025 | Non-covered Recipient Entity EIRVERA LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211600339 |
| Principal investigator 1 | Genentech, Inc. | $146.00 | 09/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211637190 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,809.90 | 09/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236153 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $12,689.90 | 09/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236158 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,029.90 | 09/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236163 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $23,983.40 | 09/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236168 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $19,700.80 | 09/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236171 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,548.00 | 09/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236176 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634431 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,205.00 | 08/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175392010 |
| Principal investigator 1 | ABBVIE INC. | $37,760.14 | 08/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY EICHENBAUM WHITE AND CRANE MDS PA | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202506075 |
| Principal investigator 1 | Genentech, Inc. | $914.00 | 08/27/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646625 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,754.94 | 08/25/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391946 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,939.00 | 08/25/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391986 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $272,798.10 | 08/22/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236148 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,663.00 | 08/20/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175392020 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,577.24 | 08/20/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221809663 |
| Principal investigator 1 | ABBVIE INC. | $7,572.56 | 08/13/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY EICHENBAUM WHITE AND CRANE MDS PA | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202504459 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,152.00 | 08/06/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236140 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $118,293.30 | 08/06/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236143 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,445.00 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175392037 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,379.56 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808630 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,833.02 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808685 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,491.56 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808693 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,854.73 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808728 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,241.13 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808760 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,564.33 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808889 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,833.02 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808936 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,419.47 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808967 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,564.33 | 08/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808986 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634429 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,896.53 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807928 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,032.53 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807934 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,896.53 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807941 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,512.33 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807947 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,512.33 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807956 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,123.60 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236137 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.14 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221804 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221806 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $516.82 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221808 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $93.80 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221814 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221816 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $264.60 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $249.48 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221820 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $222.86 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221822 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $115.88 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221824 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $185.71 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221826 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $213.93 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221828 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.57 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221830 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $609.84 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $79.20 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.14 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221836 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221838 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $516.82 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221840 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $93.80 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221842 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.36 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221844 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.91 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221846 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.97 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221848 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $226.90 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221850 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221852 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $646.80 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221854 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221856 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $105.00 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221858 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.36 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221860 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.91 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221862 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.97 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221864 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $226.90 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221866 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221868 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $646.80 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221870 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221872 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $105.00 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221874 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.00 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221876 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $71.31 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221878 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.57 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221880 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $71.31 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $297.13 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221884 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.57 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221886 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $487.29 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221888 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $88.44 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221890 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157.57 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221894 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.63 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221896 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $264.60 | 07/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184221898 |
| Principal investigator 1 | Genentech, Inc. | $39,029.00 | 07/28/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,990.00 | 07/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175392005 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,454.95 | 07/25/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 07/24/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy | No dispute reported | 06/30/2026 | 1220634519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,250.00 | 07/24/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy | No dispute reported | 06/30/2026 | 1220634521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,250.00 | 07/24/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy | No dispute reported | 06/30/2026 | 1220634523 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,663.00 | 07/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175391976 |
| Principal investigator 1 | Janssen Research & Development, LLC | $610.00 | 07/18/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175391920 |
| Principal investigator 1 | Genentech, Inc. | $25,119.00 | 07/07/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,748.00 | 07/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391970 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,844.50 | 07/02/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236120 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,168.90 | 07/02/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236125 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634427 |
| Principal investigator 1 | Genentech, Inc. | $49,448.00 | 06/25/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646557 |
| Principal investigator 1 | Genentech, Inc. | $4,296.00 | 06/25/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646571 |
| Principal investigator 1 | Genentech, Inc. | $3,926.00 | 06/23/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646562 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,096.60 | 06/23/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236088 |
| Principal investigator 1 | Genentech, Inc. | $11,251.00 | 06/17/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646723 |
| Principal investigator 1 | Genentech, Inc. | $1,257.00 | 06/11/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646565 |
| Principal investigator 1 | Janssen Research & Development, LLC | $63,398.00 | 06/09/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391891 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,809.90 | 06/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806455 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,106.00 | 06/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806465 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,640.04 | 06/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806471 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 06/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806479 |
| Principal investigator 1 | Genentech, Inc. | $22,428.00 | 06/02/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646662 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,389.00 | 06/02/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634425 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,986.80 | 05/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236084 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,106.00 | 05/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806167 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,809.90 | 05/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806239 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,577.24 | 05/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806247 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,577.24 | 05/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806254 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 05/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806263 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,207.99 | 05/28/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407774 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 05/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805880 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 05/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805889 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,702.40 | 05/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805958 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,121.80 | 05/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236071 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,014.95 | 05/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236076 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,506.70 | 05/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236080 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,100.00 | 05/26/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175391939 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $1,300.00 | 05/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TAMPA BAY PL | A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) | No dispute reported | 06/30/2026 | 1185543450 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,663.00 | 05/23/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175392053 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,121.80 | 05/23/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236064 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,121.80 | 05/23/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236068 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 05/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805711 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 05/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805720 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $56,770.40 | 05/16/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236054 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 05/15/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805426 |
| Principal investigator 1 | Genentech, Inc. | $3,008.00 | 05/14/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646608 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $22,324.50 | 05/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236045 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,440.00 | 05/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236050 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,106.00 | 05/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805308 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,809.90 | 05/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805316 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $11,691.40 | 05/09/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236037 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,026.75 | 05/09/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236041 |
| Recipient | F. Hoffmann-La Roche AG | $414.17 | 05/08/2025 | Covered Recipient Physician | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211535288 |
| Recipient | F. Hoffmann-La Roche AG | $2,130.00 | 05/04/2025 | Covered Recipient Physician | Real-world treatment patterns in patients with macular edema (ME) secondary to non-infectious uveitis (NIU) in the United States | No dispute reported | 06/30/2026 | 1211535296 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634423 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,379.56 | 05/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805017 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,419.47 | 05/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805025 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,491.56 | 05/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805033 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,419.47 | 05/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805043 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,379.56 | 05/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805052 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 04/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804938 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 04/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804945 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 04/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804952 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 04/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804960 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $44,719.20 | 04/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236033 |
| Principal investigator 1 | Roche TCRC, Inc. | $6,556.00 | 04/30/2025 | Non-covered Recipient Entity Pautler,Cohen,Findlay and Eichenbaum MD's | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211637241 |
| Principal investigator 1 | Genentech, Inc. | $4,946.00 | 04/29/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646680 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,207.99 | 04/28/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404974 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,585.32 | 04/28/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405930 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,578.00 | 04/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391952 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,980.91 | 04/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221803731 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,858.13 | 04/28/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221803748 |
| Principal investigator 1 | Genentech, Inc. | $4,308.00 | 04/25/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646588 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,479.60 | 04/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221803626 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 04/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221803634 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $648.01 | 04/23/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225404554 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $6,000.00 | 04/23/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225404950 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $730.78 | 04/23/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225404952 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $730.78 | 04/23/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225405100 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $188.41 | 04/23/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225405188 |
| Principal investigator 1 | Genentech, Inc. | $914.00 | 04/23/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,139.00 | 04/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391910 |
| Principal investigator 1 | Genentech, Inc. | $267.79 | 04/16/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646685 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,454.98 | 04/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221803259 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 04/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221803265 |
| Principal investigator 1 | Genentech, Inc. | $22,270.00 | 04/09/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211637177 |
| Principal investigator 1 | Genentech, Inc. | $12,205.00 | 04/08/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646616 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $345.00 | 04/04/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404399 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $275.00 | 04/04/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405426 |
| Principal investigator 1 | Genentech, Inc. | $126.00 | 04/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211637182 |
| Principal investigator 1 | Genentech, Inc. | $86.84 | 04/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211637186 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 04/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221803054 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,809.90 | 04/04/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221803063 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,000.00 | 04/02/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184181046 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,260.00 | 04/02/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184181048 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634421 |
| Principal investigator 1 | Genentech, Inc. | $650.00 | 04/01/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646605 |
| Principal investigator 1 | Genentech, Inc. | $4,946.00 | 04/01/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646675 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,095.67 | 04/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802528 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,036.33 | 04/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802536 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,980.91 | 04/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802543 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,426.11 | 04/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802551 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,146.13 | 04/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802560 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,556.53 | 04/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802572 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,556.53 | 04/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802579 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,710.81 | 04/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221803014 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,710.81 | 04/01/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221803023 |
| Recipient | F. Hoffmann-La Roche AG | $753.57 | 03/31/2025 | Covered Recipient Physician | Real-world treatment patterns in patients with macular edema (ME) secondary to non-infectious uveitis (NIU) in the United States | No dispute reported | 06/30/2026 | 1211535299 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,205.00 | 03/31/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391981 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,585.32 | 03/27/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404147 |
| Principal investigator 1 | Genentech, Inc. | $7,273.00 | 03/26/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646611 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $44,517.20 | 03/26/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236116 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $730.78 | 03/25/2025 | Non-covered Recipient Entity Retina Vitreous Associates Medical Group | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225403483 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $6,000.00 | 03/25/2025 | Non-covered Recipient Entity Retina Vitreous Associates Medical Group | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225403729 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $188.41 | 03/25/2025 | Non-covered Recipient Entity Retina Vitreous Associates Medical Group | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225403973 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $648.01 | 03/25/2025 | Non-covered Recipient Entity Retina Northwest PC | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225404954 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $730.78 | 03/25/2025 | Non-covered Recipient Entity Retina Vitreous Associates Medical Group | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225405190 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 03/25/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $319.68 | 03/25/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 03/25/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 03/25/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634419 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,403.11 | 03/24/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405932 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 03/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802421 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,106.00 | 03/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802426 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,370.45 | 03/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802432 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 03/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802442 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 03/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802450 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,714.85 | 03/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802458 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,577.24 | 03/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802466 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 03/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221802474 |
| Principal investigator 1 | Genentech, Inc. | $914.00 | 03/21/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646591 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $21,218.40 | 03/21/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236104 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,808.40 | 03/21/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236108 |
| Principal investigator 1 | Genentech, Inc. | $17,139.78 | 03/20/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646599 |
| Principal investigator 1 | Genentech, Inc. | $13,002.10 | 03/20/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646602 |
| Principal investigator 1 | Genentech, Inc. | $5,812.67 | 03/20/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646671 |
| Principal investigator 1 | Genentech, Inc. | $6,061.00 | 03/20/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646731 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,279.04 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802198 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,640.04 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802206 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,427.45 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802213 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,638.75 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802220 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,640.04 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802225 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,640.04 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802241 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,535.56 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802249 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,314.19 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802261 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802269 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802275 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,263.63 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802283 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,000.00 | 03/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184174940 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,570.00 | 03/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175391963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,100.00 | 03/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175392060 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,275.39 | 03/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802054 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,809.90 | 03/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802063 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,106.00 | 03/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802071 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $70,779.60 | 03/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236097 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.17 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $227.72 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157835 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.96 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157837 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157841 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157843 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $354.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157845 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $193.60 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157847 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.17 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157849 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $227.72 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157851 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.96 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157853 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $356.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157855 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157857 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157859 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $351.22 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157863 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $276.21 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184157865 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158191 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158193 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $220.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158197 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $178.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158199 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158201 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158203 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158205 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158207 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158209 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.09 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158211 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158213 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158215 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $227.72 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.96 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184158221 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $356.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166567 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166571 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166573 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166575 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $193.60 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166577 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.17 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166579 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $227.72 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166583 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166587 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166589 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $178.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $220.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166595 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.95 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166597 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $305.20 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166813 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166815 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166817 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $193.60 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.17 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166821 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166823 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.09 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166827 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166829 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166831 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166835 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166837 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $325.87 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166839 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166841 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.96 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167049 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $356.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167053 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.95 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167055 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167057 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $351.22 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167059 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $356.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167061 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167063 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167065 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.09 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167067 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $178.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167069 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.95 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $305.20 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167075 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $354.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167077 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167335 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167337 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $193.60 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.17 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $227.72 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.96 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $220.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167351 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $354.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167355 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167357 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.09 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167363 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167367 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167651 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167655 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $178.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167657 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $220.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167659 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $325.87 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167663 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $351.22 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $276.21 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167669 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $289.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167677 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167679 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167681 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $325.87 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167909 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.95 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $220.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.95 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $305.20 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $325.87 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167929 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.96 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167933 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $356.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184167935 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168167 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $354.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168169 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168171 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168173 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168177 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168179 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168181 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168183 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $289.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $325.87 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168191 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168193 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $178.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168195 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $356.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $351.22 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168426 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $276.21 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168428 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $289.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168430 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168432 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168434 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168436 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $289.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168440 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168442 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168444 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168446 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168448 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168450 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168696 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168698 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $351.22 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168700 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $276.21 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168702 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $289.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168704 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168706 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168708 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168710 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168712 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168714 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168716 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168718 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.09 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168720 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168722 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168724 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168994 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168996 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184168998 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $178.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169000 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $220.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169002 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.95 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169004 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $356.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169006 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169010 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169012 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169014 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $354.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169016 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169018 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $354.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169022 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169024 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169302 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $227.72 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169304 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.96 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169306 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $305.20 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169308 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169310 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169312 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $193.60 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169314 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $276.21 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169316 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169318 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $193.60 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169320 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.17 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169322 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169324 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169326 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169328 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169330 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169660 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169662 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $351.22 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169664 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $276.21 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169666 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $289.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169668 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169670 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169672 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169674 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $305.20 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169676 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169678 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $349.66 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $325.87 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169978 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169980 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169982 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $354.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169984 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169986 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $289.47 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169988 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169990 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.17 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169992 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169994 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.09 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169996 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169998 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170000 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170002 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170004 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.68 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170006 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $178.45 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170362 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $220.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170366 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170368 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $429.09 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170370 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170372 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170374 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $287.91 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170376 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $325.87 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170378 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.95 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170380 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $351.22 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170382 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $276.21 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170384 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $305.20 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170388 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170390 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.70 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170392 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $193.60 | 03/07/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184170394 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,486.53 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801793 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,230.93 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801802 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,095.67 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801810 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,710.81 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801817 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,426.11 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801829 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,095.67 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801839 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,980.91 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801846 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,710.81 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801856 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,095.67 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801864 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,980.91 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801871 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,426.11 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801880 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,095.67 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801888 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,426.11 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801896 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,036.33 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801906 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,093.60 | 03/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236093 |
| Principal investigator 1 | Janssen Research & Development, LLC | $49,636.00 | 03/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634411 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,403.11 | 02/28/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404790 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,207.99 | 02/27/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404976 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,403.11 | 02/27/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405228 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,207.99 | 02/27/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405230 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,403.11 | 02/27/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405934 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,207.00 | 02/24/2025 | Non-covered Recipient Entity Pautler,Cohen,Findlay and Eichenbaum MD's | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211637220 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,064.00 | 02/21/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175392065 |
| Principal investigator 1 | Genentech, Inc. | $5,615.73 | 02/19/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646668 |
| Principal investigator 1 | Genentech, Inc. | $2,477.11 | 02/19/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646727 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 02/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801233 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,545.24 | 02/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801240 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 02/19/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801249 |
| Principal investigator 1 | Genentech, Inc. | $4,255.00 | 02/18/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211646581 |
| Principal investigator 1 | Genentech, Inc. | $39,499.00 | 02/18/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211646665 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,366.00 | 02/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175392000 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,223.22 | 02/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801168 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,122.60 | 02/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801176 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,132.11 | 02/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801186 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,640.04 | 02/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801192 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 02/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801197 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,105.99 | 02/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801204 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,096.98 | 02/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801214 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,491.27 | 02/17/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801222 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,640.04 | 02/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801108 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,809.90 | 02/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801116 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,640.04 | 02/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801123 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,106.00 | 02/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801129 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,714.85 | 02/14/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801136 |
| Principal investigator 1 | Alcon Research LLC | $2,021.60 | 02/13/2025 | Non-covered Recipient Entity Pautler Cohen Findlay Eichenbaum | A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel-Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1220912858 |
| Principal investigator 1 | Alcon Research LLC | $325.00 | 02/13/2025 | Non-covered Recipient Entity Pautler Cohen Findlay Eichenbaum | A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel-Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1220912860 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $111,787.98 | 02/12/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICH | A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) | No dispute reported | 06/30/2026 | 1185543448 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 02/06/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800829 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,121.80 | 02/05/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236017 |
| Principal investigator 1 | Genentech, Inc. | $935.07 | 02/04/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646584 |
| Principal investigator 1 | Genentech, Inc. | $6,944.00 | 02/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211637172 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,650.00 | 02/03/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 02/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634407 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 02/01/2025 | Non-covered Recipient Entity Retina Vitreous Associates Of Florida-Saint Petersburg | -Ph II (PoCC/PoCP) GA 12m treatment | No dispute reported | 06/30/2026 | 1220634409 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 01/31/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221800722 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,000.00 | 01/31/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184151270 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,403.11 | 01/30/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225403369 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,403.11 | 01/30/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225403371 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,403.11 | 01/30/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404616 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,207.99 | 01/30/2025 | Non-covered Recipient Entity Pautler Cohen Findlay And Eichenbaum Mds Pa | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406872 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,809.90 | 01/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800660 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $566.05 | 01/30/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800667 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $188,009.34 | 01/30/2025 | Non-covered Recipient Entity PAULTER COHEN FINDLAY AND EICHENBAUM MDS PA RETINA VITREOUS ASSOCIATES FLORIDA | A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1190308434 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $50,511.35 | 01/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236027 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,014.95 | 01/29/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236031 |
| Principal investigator 1 | Genentech, Inc. | $977.93 | 01/28/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211646577 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,088.33 | 01/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800100 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,015.56 | 01/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800107 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,419.47 | 01/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800116 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,379.56 | 01/27/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800124 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,844.50 | 01/24/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236023 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $12,567.80 | 01/22/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236021 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,502,868.63 | 01/21/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA | A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1190301993 |
| Principal investigator 1 | Roche TCRC, Inc. | $10,975.00 | 01/21/2025 | Non-covered Recipient Entity Pautler,Cohen,Findlay and Eichenbaum MD's | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211637226 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,187.00 | 01/20/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175392026 |
| Principal investigator 1 | Roche TCRC, Inc. | $11,207.00 | 01/14/2025 | Non-covered Recipient Entity Pautler,Cohen,Findlay and Eichenbaum MD's | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211637236 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,721.00 | 01/10/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175391886 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $76,248.18 | 01/10/2025 | Non-covered Recipient Entity RETINA VITREOUS ASSOCIATES OF FLORIDA | ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study | No dispute reported | 06/30/2026 | 1190301995 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,809.90 | 01/09/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221798859 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,106.00 | 01/09/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221798865 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,049.48 | 01/08/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184146398 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,049.48 | 01/08/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184146400 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,049.48 | 01/08/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184146402 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,904.95 | 01/06/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221798809 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,577.24 | 01/06/2025 | Non-covered Recipient Entity PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221798818 |
| Principal investigator 1 | Roche TCRC, Inc. | $215.74 | 01/06/2025 | Non-covered Recipient Entity Pautler,Cohen,Findlay and Eichenbaum MD's | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211637233 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $166,174.00 | 1 |
| PY2024 | Value of interest | $193,594.00 | 1 |
| PY2023 | Amount invested | $18,355.00 | 1 |
| PY2023 | Value of interest | $27,418.00 | 1 |
| PY2022 | Amount invested | $0.00 | 2 |
| PY2022 | Value of interest | $50,000.00 | 2 |
| PY2021 | Amount invested | $0.00 | 2 |
| PY2021 | Value of interest | $50,866.84 | 2 |
| PY2020 | Amount invested | $0.00 | 2 |
| PY2020 | Value of interest | $50,866.84 | 2 |
| PY2019 | Amount invested | $0.00 | 2 |
| PY2019 | Value of interest | $50,866.84 | 2 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
10 records · PY2019–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | US Retina LLC | $166,174.00 | $193,594.00 | Membership Interest | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1143634356 |
| PY2023 | US Retina LLC | $18,355.00 | $27,418.00 | Membership Interest | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1052376953 |
| PY2022 | US Retina LLC | $0.00 | $49,999.99 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 951870023 |
| PY2022 | US Retina LLC | $0.00 | $0.01 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 951870045 |
| PY2021 | US Retina LLC | $0.00 | $50,866.83 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 856669209 |
| PY2021 | US Retina LLC | $0.00 | $0.01 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 856669245 |
| PY2020 | US Retina LLC | $0.00 | $50,866.83 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 714311503 |
| PY2020 | US Retina LLC | $0.00 | $0.01 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 714311541 |
| PY2019 | US Retina LLC | $0.00 | $50,866.83 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 655843207 |
| PY2019 | US Retina LLC | $0.00 | $0.01 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 655843285 |